Keyphrases
Head-and-neck Cancer
90%
Anaplastic Thyroid Cancer
89%
Head-and-neck
79%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
59%
Tumor
55%
Squamous Cell Carcinoma of Head
50%
Overall Survival
47%
Programmed Death-ligand 1 (PD-L1)
44%
Thyroid Cancer
40%
High-risk Human Papillomavirus (HR-HPV)
37%
Induction Chemotherapy
34%
Locally Advanced
33%
Intensity-modulated Radiation Therapy
31%
Phase II Trial
30%
Recurrent Metastatic
30%
Immune Checkpoint Blockade
30%
Immune Checkpoint Inhibitors
30%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
28%
Medullary Thyroid Cancer
28%
HPV16
27%
Progression-free Survival
25%
Nasopharyngeal Carcinoma
25%
Squamous Cell Cancer
24%
Papillary Thyroid Carcinoma
24%
Poorly Differentiated Thyroid Carcinoma
23%
Cisplatin
23%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
22%
Everolimus
21%
Chemotherapy
20%
Radiation Therapy
19%
Nivolumab
19%
Metastatic Squamous Cell Carcinoma
19%
Cancer Patients
18%
Concurrent Chemoradiotherapy
18%
PD-L1 Expression
17%
Tyrosine Kinase Inhibitor
17%
Metastatic Adenoid Cystic Carcinoma
16%
Phase II Study
16%
Clinical Outcomes
16%
Randomized Phase III Trial
16%
Chemoradiotherapy
15%
Histopathological Features
14%
Fluorouracil
14%
Adenoid Cystic Carcinoma
14%
Papillary Thyroid Cancer
14%
Anaplastic
14%
Differentiated Thyroid Carcinoma
13%
Docetaxel
13%
Partial Response
13%
Sequential Therapy
13%
Medicine and Dentistry
Neoplasm
100%
Neck
76%
Anaplastic Thyroid Carcinoma
71%
Squamous Cell Carcinoma
69%
Head and Neck Cancer
66%
Overall Survival
59%
Diseases
59%
Thyroid Cancer
41%
Oropharynx Carcinoma
37%
Wart Virus
37%
Chemoradiotherapy
35%
Intensity Modulated Radiation Therapy
31%
Papillary Thyroid Cancer
30%
Radiation Therapy
28%
Induction Chemotherapy
28%
Progression Free Survival
27%
Recurrent Disease
26%
Oral Cavity
26%
Cylindroma
26%
Programmed Death-Ligand 1
25%
Head and Neck Squamous Cell Carcinoma
22%
Nasopharynx Carcinoma
22%
Immune Checkpoint Inhibitor
21%
Immune Checkpoint Blockade
19%
Nivolumab
19%
Clinical Trial
19%
Everolimus
18%
Merkel Cell Carcinoma
18%
Epstein Barr Virus
18%
Cisplatin
18%
Cancer Cell
17%
Percutaneous Endoscopic Gastrostomy
17%
Squamous Cell
16%
Radioactive Iodine
16%
Combination Therapy
15%
Fluorouracil
15%
Programmed Death 1 Receptor
15%
Oropharynx Squamous Cell Carcinoma
15%
Poorly Differentiated Thyroid Cancer
15%
Tumor Progression
15%
Metastatic Carcinoma
15%
Malignant Neoplasm
14%
Biological Marker
14%
Disease Free Survival
14%
T Cell
13%
Larynx
13%
Differentiated Thyroid Cancer
13%
Cancer
13%
Docetaxel
13%
Patient-Reported Outcome
12%
Pharmacology, Toxicology and Pharmaceutical Science
Anaplastic Thyroid Carcinoma
61%
Neoplasm
61%
Chemotherapy
55%
Thyroid Cancer
47%
Diseases
46%
Squamous Cell Carcinoma
45%
Human Papillomavirus
43%
Overall Survival
42%
Head and Neck Cancer
40%
Chemoradiation Therapy
37%
Oropharynx Carcinoma
37%
Malignant Neoplasm
35%
Oropharynx Cancer
31%
Progression Free Survival
26%
Everolimus
21%
Adenoid Cystic Carcinoma
19%
Clinical Trial
19%
Radioactive Iodine
19%
Differentiated Thyroid Cancer
19%
Immunotherapy
17%
Fluorouracil
16%
Combination Therapy
15%
Nasopharynx Carcinoma
15%
Recurrent Disease
15%
Oropharynx Squamous Cell Carcinoma
15%
Immune Checkpoint Inhibitor
14%
Programmed Death 1 Receptor
13%
Docetaxel
13%
Cisplatin
12%
Merkel Cell Carcinoma
12%
Nucleic Acid
12%
Trastuzumab
12%
Pembrolizumab
11%
Programmed Death 1 Ligand 1
11%
Protein Tyrosine Kinase Inhibitor
10%
Human Papillomavirus Type 16
10%
Phase II Trials
9%
Carcinogenesis
9%
Tumor Growth
9%
Biological Marker
9%
Salivary Duct Carcinoma
9%
Papillomavirus Infection
8%
Therapeutic Vaccine
7%
Protein Kinase B
7%
Phase III Trials
7%
Dysphagia
7%
Disease Exacerbation
7%
Prevalence
7%
Randomized Controlled Trial
7%
Tumor Vaccine
7%